You are here
Lilly has issued an advanced press release on its SPIRIT-H2H trial, wherein ixekizumab (Taltz) was shown to be more effective than than adalimumab (Humira) in a 24 week psoriatic arthritis study.
SPIRIT-H2H study was designed as a large head-to-head (H2H) superiority study to assess the efficacy and safety of ixekizumab versus adalimumab active psoriatic arthritis (PsA) patients who are biologic naive.
A total of 566 active PsA patients were randomized and either given ixekizumab with a 160-mg starting dose followed by 80 mg every four weeks or adalimumab 40 mg every two weeks). At 24 weeks.
The actual numbers were not made available ixekizumab was better than adalimumab in both primary endpoints of an ACR50 response and complete skin clearance as by PASI. Apparently no new safety signals were detected in the SPIRIT-H2H trial.
These results have not yet been vetted by peer review or presented at a national convention.